References
- Adam RD, Coriu D, Jercan A, et al. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. ESC Heart Failure. 2021 Aug;8(4):2380-96. doi: 10.1002/ehf2.13443
- Stern LK, Kittleson MM. Updates in Cardiac Amyloidosis Diagnosis and Treatment. Curr Oncol Rep. 2021 Mar 16;23(4): 47. doi: 10.1007/s11912-021-01028-8
- Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012 Dec 20;30(36):4541-9. doi: 10.1200/JCO.2011.37.7614
- Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Blood. 2020 Dec 3;136(23):2620-2627. doi: 10.1182/blood.2020006913
- Manwani R, Foard D, Mahmood S, et al. Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis. Haematologica. 2018 Apr;103(4):e165-e168. doi: 10.3324/haematol.2017.178095
- Sidana S, Milani P, Binder M, et al. A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. Blood Cancer J. 2020 Apr 14;10(4):41. doi: 10.1038/s41408-020-0306-5
- Salinaro F, Meier-Ewert HK, Miller EJ, et al. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2017 Sep 1;18(9):1057-1064. doi: 10.1093/ehjci/jew298
- Martinez-Naharro A, Abdel-Gadir A, Treibel TA, et al. Abstract 14407: Regression of Cardiac AL Amyloid by Cardiovascular Magnetic Resonance. Circulation. 2016 Nov 11;134(suppl_1):A14407.
- Sidiqi MH, Aljama MA, Buadi FK, et al. Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. J Clin Oncol. 2018 May 1;36(13):1323-1329. doi: 10.1200/JCO.2017.76.9554
- Lilleness B, Ruberg FL, Mussinelli R, Doros G, Sanchorawala V. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood. 2019 Jan 17;133(3):215-223. doi: 10.1182/blood-2018-06-858951
- Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. J Clin Oncol. 2020 Oct 1;38(28):3252-3260. doi: 10.1200/JCO.20.01285
- Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631
- Genmab.com [Internet]. Copenhagen, Denmark; Genmab; c 2022.
Genmab Announces that Janssen has been granted U.S. FDA approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for patients with newly diagnosed light-chain (al) amyloidosis ; 2021 Jan 15 [cited 2022 Jan 5]. Available from:https://ir.genmab.com/news-releases/news-release-details/genmab-announces-janssen-has-been-granted-us-fda-approval - ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022.
A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis ; 2021 Oct 7 [cited 2022 Jan 31]. Available from:https://ClinicalTrials.gov/show/NCT04131309 - Manwani R, Mahmood S, Sachchithanantham S, et al. Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy. Br J Haematol. 2019 Dec;187(5):638-641. doi: 10.1111/bjh.16122
- Premkumar VJ, Lentzsch S, Pan S, et al. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer J. 2021 Jan 11;11(1):10. doi: 10.1038/s41408-020-00397-w
- Roussel M, Merlini G, Chevret S, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. Blood. 2020 Apr 30;135(18):1531-1540. doi: 10.1182/blood.2019004369
- Sanchorawala V, Sarosiek S, Schulman A, et al. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. 2020 Apr 30;135(18):1541-1547. doi: 10.1182/blood.2019004436
- Warsame R, LaPlant B, Kumar SK, et al. Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. Blood Cancer J. 2020 Jan 8;10(1):4. doi: 10.1038/s41408-019-0266-9
- Dispenzieri A, Dingli D, Kumar SK, et al. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol. 2010 Oct;85(10):757-9. doi: 10.1002/ajh.21822
- Dispenzieri A, Kastritis E, Wechalekar AD, et al. Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician’s Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). Blood. 2019 Nov 13;134(Supplement_1):139. doi: 10.1182/blood-2019-124409
- Reuters.com [Internet]. Canary Wharf, London: Reuters;c2022.
BRIEF: Prothena Discontinues Development of NEOD001 for AL Amyloidosis ; 2018 Apr 13 [cited 2022 Jan 5]. Available from:https://www.reuters.com/article/brief-prothena-discontinues-development-idCNASC09WS6 - Valent J, Silowsky J, Kurman MR, et al. Cael-101 Is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (CyborD): A Phase 2 Dose-Finding Study (NCT04304144). Blood. 2020 Dec 6;136(Supplement 1):26-7. doi: 10.1182/blood-2020-139323
- ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine;c 2022.
A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis ;2021 Dec 7 [cited 2022Jan 31]. Available from:https://ClinicalTrials.gov/show/NCT04512235 - ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022.
A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis ; 2021 Dec 7 [cited 2022 Jan 31]. Available from:https://ClinicalTrials.gov/show/NCT04504825 - Ehrnhoefer DE, Bieschke J, Boeddrich A, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol. 2008 Jun;15(6):558-66. doi: 10.1038/nsmb.1437
- ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022.
Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis ; 2018 Mar 21 [cited 2022 Jan 31]. Available from:https://ClinicalTrials.gov/show/NCT01511263 - ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022.
A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL) ; 2017 Oct 17 [cited 2022 Jan 31]. Available from:https://ClinicalTrials.gov/show/NCT02015312 - Meshitsuka S, Shingaki S, Hotta M, et al. Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis. Int J Hematol. 2017 Mar; 105(3):295-308. doi: 10.1007/s12185-016-2112-1
- Ward JE, Ren R, Toraldo G, et al. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood. 2011 Dec 15;118(25):6610-7. doi: 10.1182/blood-2011-04-351643
- Diomede L, Rognoni P, Lavatelli F, et al. A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood. 2014 Jun 5;123(23):3543-52. doi: 10.1182/blood-2013-10-525634
- Wechalekar AD, Whelan C. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis. Blood Cancer J. 2017 Mar 24;7(3):
e546 . doi: 10.1038/bcj.2017.26 - Kumar SK, Dispenzieri A, Lacy MQ, et al. Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation. Blood. 2012;120(21):3138. doi: 10.1182/blood.V120.21.3138.3138
- Shen KN, Fu WJ, Wu Y, et al. Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial. 2022 Jan 4;145(1):8-17. doi: 10.1161/CIRCULATIONAHA.121.055953
- ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022.
A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy ; 2021 Jan 26 [cited 2022 Jan 31]. Available from:https://ClinicalTrials.gov/show/NCT03474458 - Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153
- Solomon SD, Adams D, Kristen A, et al. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation. 2019 Jan 22;139(4):431-443. doi: 10.1161/CIRCULATIONAHA.118.035831
- ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022.
APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) ; 2022 Jan 13 [cited 2022 Jan 31]. Available from:https://ClinicalTrials.gov/show/NCT03997383 - Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793
- Dasgupta NR, Rissing SM, Smith J, Jung J, Benson MD. Inotersen therapy of transthyretin amyloid cardiomyopathy. Amyloid. 2020 Mar;27(1):52-58. doi: 10.1080/13506129.2019.1685487
- ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022.
24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients ; 2020 Dec 7 [cited 2022 Jan 31]. Available from:https://ClinicalTrials.gov/show/NCT03702829 - Judge DP, Kristen AV, Grogan M, et al. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. 2020 Jun;34(3):357-370. doi: 10.1007/s10557-019-06919-4
- ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022.
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy ; 2022 Jan 13 [cited 2022 Jan 31]. Available from:https://ClinicalTrials.gov/show/NCT04153149 - ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022.
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) ; 2022 Jan 11 [cited 2022 Jan 31]. Available from:https://ClinicalTrials.gov/show/NCT04136171 - Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med. 2021 Aug 5;385(6):493-502. doi: 10.1056/NEJMoa2107454
- Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid. 2006 Dec;13(4):236-49. doi: 10.1080/13506120600960882
- Castaño A, Helmke S, Alvarez J, Delisle S, Maurer MS. Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail. Nov-Dec 2012;18(6):315-9. doi: 10.1111/j.1751-7133.2012.00303.x
- Rosenblum H, Castano A, Alvarez J, Goldsmith J, Helmke S, Maurer MS. TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis. Circ Heart Fail. 2018 Apr;11(4):
e004769 . doi: 10.1161/CIRCHEARTFAILURE.117.004769 - Sekijima Y, Tojo K, Morita H, Koyama J, Ikeda S. Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid. 2015;22(2):79-83. doi: 10.3109/13506129.2014.997872
- Wixner J, Westermark P, Ihse E, Pilebro B, Lundgren HE, Anan I. The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition. Amyloid. 2019;26(sup1):39-40. doi: 10.1080/13506129.2019.1593133
- Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689
- Kazi DS, Bellows BK, Baron SJ, et al. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation. 2020 Apr 14;141(15):1214-1224. doi: 10.1161/CIRCULATIONAHA.119.045093
- Ji AX, Wong PW, Betz A, Sinha U. Abstract 13847: Differential Transthyretin Binding, Kinetic Stability and Additive Ex Vivo Stabilization by AG10 Compared to Tafamidis. Circulation. 2019 Nov 19;140(Suppl_1):A13847-A. doi: 10.1161/circ.140.suppl_1.13847
- ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022.
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy ; 2021 Dec 30 [cited 2022 Jan 31]. Available from:https://ClinicalTrials.gov/show/NCT03860935 - Ferreira N, Cardoso I, Domingues MR, et al. Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Lett. 2009 Nov 19;583(22):3569-76. doi: 10.1016/j.febslet.2009.10.062
- Ferreira N, Saraiva MJ, Almeida MR. Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: “in vivo” evidence from FAP mice models. PLoS One. 2012;7(1):
e29933 . doi: 10.1371/journal.pone.0029933 - aus dem Siepen F, Bauer R, Aurich M, et al. Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. Drug Des Devel Ther. 2015 Dec 4;9:6319-25. doi: 10.2147/DDDT.S96893
- aus dem Siepen F, Buss SJ, Andre F, et al. Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study. Clin Res Cardiol. 2015 Aug;104(8):640-7. doi: 10.1007/s00392-015-0826-3
- Kristen AV, Lehrke S, Buss S, et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol. 2012 Oct;101(10):805-13. doi: 10.1007/s00392-012-0463-z
- Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ. Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med. 2010 Jul 30;8:74. doi: 10.1186/1479-5876-8-74
- Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid. 2012 Jun;19 Suppl 1:34-6. doi: 10.3109/13506129.2012.678508
- Wixner J, Pilebro B, Lundgren HE, Olsson M, Anan I. Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis. Amyloid. 2017 Mar;24(sup1):78-79. doi: 10.1080/13506129.2016.1269739
- Karlstedt E, Jimenez-Zepeda V, Howlett JG, White JA, Fine NM. Clinical Experience With the Use of Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis. J Card Fail. 2019 Mar;25(3):147-153. doi: 10.1016/j.cardfail.2019.01.006
- ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022.
A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin ; 2020 May 14 [cited 2022 Jan 31]. Available from:https://ClinicalTrials.gov/show/NCT03481972 - ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022.
A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis ; 2020 Aug 20 [cited 2022 Feb 19]. Available from:https://ClinicalTrials.gov/show/NCT03336580 - Michalon A, Hagenbuch A, Huy C, et al. A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nat Commun. 2021 May 25;12(1):3142. doi: 10.1038/s41467-021-23274-x
- ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022.
First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy ; 2021 Aug 10 [cited 2022 Jan 31]. Available from:https://ClinicalTrials.gov/show/NCT04360434 - Richards DB, Cookson LM, Berges AC, et al. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med. 2015 Sep 17;373(12):1106-14. doi: 10.1056/NEJMoa1504942
- ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c 2022.
Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698 ;2019 Oct 16 [cited 2022 Jan 31]. Available from:https://ClinicalTrials.gov/show/NCT03044353 - Wechalekar AD, Gillmore JD, Bird J, et al. Guidelines on the management of AL amyloidosis. 2015 Jan;168(2):186-206. doi: 10.1111/bjh.13155
- Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020 Jul 7;142(1):e7-e22. doi: 10.1161/CIR.0000000000000792
- Pérez-Lloret S, Quarracino C, Otero-Losada M, Rascol O. Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases. Expert Opin Pharmacother. 2019 Apr;20(6):635-645. doi: 10.1080/14656566.2019.1574746
- Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med. 2008 Feb 7;358(6):615-24. doi: 10.1056/NEJMcp074189
- Gertz MA, Falk RH, Skinner M, Cohen AS, Kyle RA. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol. 1985 Jun 1;55(13 Pt 1):1645. doi: 10.1016/0002-9149(85)90995-6
- Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019 Nov;16(11):e301-e372. doi: 10.1016/j.hrthm.2019.05.007
- Donnellan E, Wazni OM, Saliba WI, et al. Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality. J Cardiovasc Electrophysiol. 2019 Nov;30(11):2427-2432. doi: 10.1111/jce.14180
- Hamon D, Algalarrondo V, Gandjbakhch E, et al. Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis. Int J Cardiol. 2016 Nov 1;222:562-568. doi: 10.1016/j.ijcard.2016.07.254
- Sanchis K, Cariou E, Colombat M, et al. Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality. Amyloid. 2019 Sep;26(3):128-138. doi: 10.1080/13506129.2019.1620724
- Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981 Jun;63(6):1285-8. doi: 10.1161/01.CIR.63.6.1285
- Muchtar E, Gertz MA, Kumar SK, et al. Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? Amyloid. 2018 Jun;25(2):86-92. doi: 10.1080/13506129.2018.1449744
- Donnellan E, Elshazly MB, Vakamudi S, et al. No Association Between CHADS-VASc Score and Left Atrial Appendage Thrombus in Patients With Transthyretin Amyloidosis. JACC Clin Electrophysiol. 2019 Dec;5(12):1473-1474. doi: 10.1016/j.jacep.2019.10.013
- Feng D, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007 Nov 20;116(21):2420-6. doi: 10.1161/CIRCULATIONAHA.107.697763
- Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017 Oct 7;38(38):2879-2887. doi: 10.1093/eurheartj/ehx350
- Nitsche C, Scully PR, Patel KP, et al. Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis. J Am Coll Cardiol. 2021 Jan 19;77(2):128-139. doi: 10.1016/j.jacc.2020.11.006
- Scully PR, Patel KP, Treibel TA, et al. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart J. 2020 Aug 1;41(29):2759-2767. doi: 10.1093/eurheartj/ehaa170
- Swiecicki PL, Edwards BS, Kushwaha SS, Dispenzieri A, Park SJ, Gertz MA. Left ventricular device implantation for advanced cardiac amyloidosis. J Heart Lung Transplant. 2013 May;32(5):563-8. doi: 10.1016/j.healun.2013.01.987
- Kittleson MM, Cole RM, Patel J, et al. Mechanical circulatory support for cardiac amyloidosis. Clin Transplant. 2019 Oct;33(10):
e13663 . doi: 10.1111/ctr.13663 - Griffin JM, Chiu L, Axsom KM, et al. United network for organ sharing outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis. Clin Transplant. 2020 Oct;34(10):
e14028 . doi: 10.1111/ctr.14028 - Kristen AV, Kreusser MM, Blum P, et al. Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. J Heart Lung Transplant. 2018 May;37(5):611-618. doi: 10.1016/j.healun.2017.11.015
- Vaidya GN, Patel JK, Kittleson M, et al. Intermediate-term outcomes of heart transplantation for cardiac amyloidosis in the current era. Clin Transplant. 2021 Jun;35(6):
e14308 . doi: 10.1111/ctr.14308 - Davis MK, Lee PH, Witteles RM. Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant. 2015 May;34(5):658-66. doi: 10.1016/j.healun.2014.09.006
- Trachtenberg BH, Kamble RT, Rice L, et al. Delayed autologous stem cell transplantation following cardiac transplantation experience in patients with cardiac amyloidosis. Am J Transplant. 2019 Oct;19(10):2900-2909. doi: 10.1111/ajt.15487
DOI: https://doi.org/10.14797/mdcvj.1050 | Journal eISSN: 1947-6108
Language: English
Page range: 59 - 72
Submitted on: Oct 13, 2021
Accepted on: Dec 7, 2021
Published on: Mar 14, 2022
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2022 Lily K. Stern, Jignesh Patel, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.